CD274 and neoplasm: As reported in the CheckMate-816 trial (NCT02998528), the magnitude of EFS benefit was greater for the patients with stage IIIA (HR 0.54) than for those with stages IB to II disease (HR 0.87) and for patients with tumor PD-L1 expression of 1% or greater (HR 0.41) than for those with PD-L1 expression lower than 1% (HR 0.85).